TW201309346A - 噴霧乾燥萬古黴素 - Google Patents
噴霧乾燥萬古黴素 Download PDFInfo
- Publication number
- TW201309346A TW201309346A TW101100376A TW101100376A TW201309346A TW 201309346 A TW201309346 A TW 201309346A TW 101100376 A TW101100376 A TW 101100376A TW 101100376 A TW101100376 A TW 101100376A TW 201309346 A TW201309346 A TW 201309346A
- Authority
- TW
- Taiwan
- Prior art keywords
- weight
- spray
- solution
- powder
- vancomycin
- Prior art date
Links
- 108010059993 Vancomycin Proteins 0.000 title claims abstract description 50
- 229960003165 vancomycin Drugs 0.000 title claims abstract description 16
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 title claims abstract description 16
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 238000001694 spray drying Methods 0.000 title claims description 28
- 238000000034 method Methods 0.000 claims abstract description 50
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 17
- 229930195725 Mannitol Natural products 0.000 claims abstract description 17
- 239000000594 mannitol Substances 0.000 claims abstract description 17
- 235000010355 mannitol Nutrition 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000007979 citrate buffer Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 46
- 229960001572 vancomycin hydrochloride Drugs 0.000 claims description 35
- LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 12
- 238000001802 infusion Methods 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 abstract description 46
- 239000000203 mixture Substances 0.000 abstract description 44
- 238000009472 formulation Methods 0.000 abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 18
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000007789 gas Substances 0.000 description 35
- 238000001035 drying Methods 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 230000008569 process Effects 0.000 description 15
- 239000008215 water for injection Substances 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000008186 active pharmaceutical agent Substances 0.000 description 9
- 238000012546 transfer Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 239000000945 filler Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000011146 sterile filtration Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000011045 prefiltration Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 108010032807 vancomycin B Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010327 methods by industry Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161429844P | 2011-01-05 | 2011-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201309346A true TW201309346A (zh) | 2013-03-01 |
Family
ID=46457949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101100376A TW201309346A (zh) | 2011-01-05 | 2012-01-04 | 噴霧乾燥萬古黴素 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8709310B2 (enExample) |
| EP (1) | EP2661254B1 (enExample) |
| JP (1) | JP5913367B2 (enExample) |
| CN (1) | CN103429228B (enExample) |
| AU (1) | AU2012204462A1 (enExample) |
| CA (1) | CA2823628A1 (enExample) |
| DK (1) | DK2661254T3 (enExample) |
| ES (1) | ES2645769T3 (enExample) |
| TW (1) | TW201309346A (enExample) |
| WO (1) | WO2012094381A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITLO20110001A1 (it) * | 2011-05-03 | 2012-11-04 | Fisiopharma Srl | Flaconi di vancomicina cloroidrata con stabilità migliorata |
| US8952105B2 (en) | 2012-05-23 | 2015-02-10 | Baker Hughes Incorporated | Variable TG article, method of making, and use of same |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| ES2693081T3 (es) * | 2013-09-30 | 2018-12-07 | Daiichi Sankyo Company, Limited | Procedimiento de producción selectiva de la forma cristalina alfa de D-manitol usando un procedimiento de secado por pulverización |
| WO2015138983A1 (en) * | 2014-03-14 | 2015-09-17 | Cutispharma, Inc. | Composition and method for vancomycin oral liquid |
| PT107568B (pt) * | 2014-03-31 | 2018-11-05 | Hovione Farm S A | Processo de secagem por atomização para a produção de pós com propriedades melhoradas. |
| AU2020237983A1 (en) * | 2019-03-08 | 2021-10-07 | Emphascience, Inc. | Stable pharmaceutical formulations of peptide and protein drugs |
| CN114432339B (zh) * | 2022-02-18 | 2023-05-26 | 重庆希尔安药业有限公司 | 一种聚乙二醇钠钾散及其制备方法 |
| CN119745821B (zh) * | 2024-11-28 | 2025-10-03 | 时森海(杭州)医药科技有限公司 | 一种盐酸万古霉素固体胶囊及其制备方法 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2911036A (en) | 1955-01-03 | 1959-11-03 | Melvin E Lazar | Spray-drying apparatus |
| DE3013839A1 (de) | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
| US4831015A (en) | 1987-08-13 | 1989-05-16 | American Cyanamid Company | High potency biomass-free avoparcin and a method for its preparation |
| CA2011365A1 (en) | 1989-03-06 | 1990-09-06 | Eugene L. Inman | Diluent formulation for daptomycin |
| JPH03193735A (ja) * | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | グリコペプチド系抗生物質の安定化組成物 |
| JPH04142149A (ja) | 1990-10-02 | 1992-05-15 | Canon Inc | ファクシミリ装置 |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| US6673335B1 (en) | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| KR100291620B1 (ko) | 1992-09-29 | 2001-10-24 | 추후제출 | 부갑상선호르몬의활성단편의폐를통한전달방법 |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| GB9406769D0 (en) | 1994-04-06 | 1994-05-25 | Btr Plc | Valve system |
| EP0758244B2 (en) | 1994-05-06 | 2008-02-13 | Pfizer Inc. | Controlled-release dosage forms of azithromycin |
| WO1995031479A1 (en) | 1994-05-18 | 1995-11-23 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| KR100215739B1 (ko) | 1994-10-13 | 1999-08-16 | 오쿠다 기요아키 | 가역성열겔화 수용성 의약 조성물을 함유하는 동결건조 제제 |
| IL116085A (en) | 1994-12-16 | 1999-12-31 | Ortho Pharma Corp | Spray dried erythropoietin |
| SI9500039B (sl) * | 1995-02-07 | 2002-02-28 | Lek, | Nov kombiniran postopek čiščenja Vankomicin hidroklorida |
| US6433344B1 (en) | 1996-05-22 | 2002-08-13 | Purepulse Technologies, Inc. | Pulsed light sterilization of drinking water and drinking water containers |
| US7038219B2 (en) | 1996-05-22 | 2006-05-02 | Purepulse Technologies, Inc. | Sterilization of packages and their contents using light |
| WO1998029098A1 (en) | 1996-12-31 | 1998-07-09 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
| JPH115743A (ja) * | 1997-06-16 | 1999-01-12 | Kayaku:Kk | バンコマイシン注射剤 |
| JP4142149B2 (ja) | 1997-07-10 | 2008-08-27 | 明治製菓株式会社 | バンコマイシンの凍結乾燥製剤 |
| US6413556B1 (en) | 1999-01-08 | 2002-07-02 | Sky High, Llc | Aqueous anti-apoptotic compositions |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| DE60017888T2 (de) * | 1999-04-05 | 2006-01-19 | Emisphere Technologies, Inc. | Dinatrium-salze, monohydrate und ethanol-solvate |
| US6253463B1 (en) | 1999-04-26 | 2001-07-03 | Niro A/S | Method of spray drying |
| US6223455B1 (en) | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| CN1188111C (zh) | 1999-10-29 | 2005-02-09 | 耐科塔医药公司 | 分散性得到改进的干粉组合物 |
| CZ20022047A3 (cs) | 1999-12-23 | 2003-09-17 | Pfizer Products Inc. | Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva |
| WO2001047542A1 (en) * | 1999-12-28 | 2001-07-05 | Meiji Seika Kaisha, Ltd. | Vancomycin preparations |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| US6730923B1 (en) | 2000-05-05 | 2004-05-04 | Purepulse Technologies, Inc. | Transmissive conveyor for use in pulsed light sterilization |
| JP4081987B2 (ja) | 2000-05-30 | 2008-04-30 | 株式会社村田製作所 | 金属粉末の製造方法，金属粉末，これを用いた導電性ペーストならびにこれを用いた積層セラミック電子部品 |
| DE10036871A1 (de) | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
| WO2002015842A2 (en) | 2000-08-23 | 2002-02-28 | Wockhardt Limited | Process for preparation of anhydrous azithromycin |
| DK1341528T3 (da) | 2000-12-07 | 2012-03-26 | Nycomed Gmbh | Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel |
| WO2002059145A1 (en) | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| AU2002246688A1 (en) | 2000-12-18 | 2002-07-30 | Altus Biologics Inc. | Methods for preparing purified daptomycin |
| US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| WO2003063822A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| EP1469830A2 (en) | 2002-02-01 | 2004-10-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| AU2003221888B2 (en) | 2002-04-11 | 2008-11-06 | Medimmune, Llc | Preservation of bioactive materials by spray drying |
| US7148211B2 (en) | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| AU2003295432A1 (en) * | 2002-11-12 | 2004-06-03 | Enzon Pharmaceuticals, Inc. | Prodrugs of vancomycin with hydrolysis resistant polymer linkers |
| US20040121003A1 (en) | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| US20050026813A1 (en) | 2003-07-30 | 2005-02-03 | Olstein Alan D. | Antibiotic-metal complexes in the detection of gram-positive bacteria and other biological analytes |
| US20060292081A1 (en) | 2003-09-15 | 2006-12-28 | Vectura Limited | Methods for preparing pharmaceutical compositions |
| US20050101547A1 (en) | 2003-11-06 | 2005-05-12 | Sadatrezaei Mohsen | Stabilized azithromycin composition |
| EP1691786A1 (en) | 2003-12-04 | 2006-08-23 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
| US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
| ATE529117T1 (de) | 2004-07-02 | 2011-11-15 | Wakamoto Pharma Co Ltd | Medizinische zusammensetzung auf wasserbasis mit azithromycin und herstellungsverfahren dafür |
| EP1781257B1 (en) * | 2004-08-13 | 2018-12-19 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| WO2006055950A1 (en) | 2004-11-18 | 2006-05-26 | Nektar Therapeutics | Pharmaceutical dry powder formulation on the basis particles comprising multiple active agents |
| US20080194820A1 (en) | 2004-12-14 | 2008-08-14 | Venkataraman Sundaram | Process For Preparing Voriconazole |
| ES2482700T3 (es) | 2005-02-14 | 2014-08-04 | Venus Remedies Limited | Terapia de combinación parenteral para enfermedades infecciosas causadas por una bacteria resistente a los medicamentos |
| US20060228251A1 (en) | 2005-04-06 | 2006-10-12 | Jagaji Holdings, Llc | Pulsed high-intensity light sterilization |
| EP2974718A1 (en) | 2005-04-29 | 2016-01-20 | Cubist Pharmaceuticals, Inc. | Therapeutic compositions |
| CN101277682B (zh) * | 2005-07-28 | 2015-07-29 | Isp投资有限公司 | 无定形依发韦仑及其生产 |
| WO2007070852A2 (en) | 2005-12-15 | 2007-06-21 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for parenteral administration |
| US7931859B2 (en) | 2005-12-22 | 2011-04-26 | Intelligent Hospital Systems Ltd. | Ultraviolet sanitization in pharmacy environments |
| US7621921B2 (en) | 2006-01-25 | 2009-11-24 | Symmetry Medical, Inc | Split thread orthopaedic implant impactor |
| CN1857716A (zh) * | 2006-03-14 | 2006-11-08 | 浙江大学 | 注射用盐酸万古霉素及其制备方法 |
| AR061889A1 (es) | 2006-07-13 | 2008-10-01 | Medichem Sa | Proceso mejorado para la preparacion de voriconazol |
| US8834929B2 (en) | 2006-07-21 | 2014-09-16 | Bend Research, Inc. | Drying of drug-containing particles |
| EP2125938A2 (en) | 2007-01-26 | 2009-12-02 | Isp Investments Inc. | Formulation process method to produce spray dried products |
| US8398732B2 (en) * | 2007-04-10 | 2013-03-19 | Gea Process Engineering Inc. | Process gas filtration |
| PL2200588T3 (pl) | 2007-09-25 | 2019-09-30 | Solubest Ltd. | Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania |
| US7795231B2 (en) | 2007-10-04 | 2010-09-14 | Insite Vision Incorporated | Concentrated aqueous azalide formulations |
| WO2009149020A1 (en) | 2008-06-04 | 2009-12-10 | Triton Thalassic Technologies, Inc. | Methods, systems and apparatus for monochromatic uv light sterilization |
| CN101613396B (zh) * | 2008-06-26 | 2016-08-17 | 浙江医药股份有限公司新昌制药厂 | 无结晶型态盐酸万古霉素及其制备方法和用途、以及它的药物组合物 |
| US20100049322A1 (en) | 2008-08-19 | 2010-02-25 | Warsaw Orthopedic, Inc. | Osteochondral repair implants and methods |
| US20100057910A1 (en) | 2008-09-02 | 2010-03-04 | International Business Machines Corporation | Concept for trusting client-side storage and distribution of asynchronous includes in an application server environment |
| CN101444510B (zh) | 2008-12-31 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 含有伏立康唑的药物制剂及其制备方法 |
| KR101101663B1 (ko) | 2009-01-13 | 2011-12-30 | (주) 제노텍 | 반코마이신 습체의 정제방법 |
| GB0902324D0 (en) | 2009-02-12 | 2009-04-01 | Powder Systems Ltd | Improvements relating to valves |
| US8431539B2 (en) | 2009-09-17 | 2013-04-30 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
| US20110124551A1 (en) | 2009-11-23 | 2011-05-26 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
| BR112012012406B1 (pt) | 2009-11-23 | 2021-11-16 | Cubist Pharmaceuticals Llc | Composições farmacêuticas sólidas de daptomicina, seu produto farmacêutico e seus métodos de fabricação |
-
2012
- 2012-01-04 CA CA2823628A patent/CA2823628A1/en not_active Abandoned
- 2012-01-04 US US13/343,297 patent/US8709310B2/en active Active
- 2012-01-04 DK DK12732323.6T patent/DK2661254T3/da active
- 2012-01-04 JP JP2013548475A patent/JP5913367B2/ja not_active Expired - Fee Related
- 2012-01-04 TW TW101100376A patent/TW201309346A/zh unknown
- 2012-01-04 CN CN201280011863.8A patent/CN103429228B/zh not_active Expired - Fee Related
- 2012-01-04 AU AU2012204462A patent/AU2012204462A1/en not_active Abandoned
- 2012-01-04 EP EP12732323.6A patent/EP2661254B1/en active Active
- 2012-01-04 ES ES12732323.6T patent/ES2645769T3/es active Active
- 2012-01-04 WO PCT/US2012/020160 patent/WO2012094381A2/en not_active Ceased
-
2014
- 2014-04-28 US US14/262,952 patent/US9023258B2/en active Active
-
2015
- 2015-05-04 US US14/703,392 patent/US9763997B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9763997B2 (en) | 2017-09-19 |
| US9023258B2 (en) | 2015-05-05 |
| US20150231197A1 (en) | 2015-08-20 |
| EP2661254B1 (en) | 2017-08-02 |
| AU2012204462A1 (en) | 2013-07-11 |
| EP2661254A4 (en) | 2015-01-28 |
| US20140235530A1 (en) | 2014-08-21 |
| CN103429228A (zh) | 2013-12-04 |
| WO2012094381A3 (en) | 2013-06-20 |
| JP2014501781A (ja) | 2014-01-23 |
| CN103429228B (zh) | 2016-10-26 |
| EP2661254A2 (en) | 2013-11-13 |
| US20130009330A1 (en) | 2013-01-10 |
| DK2661254T3 (da) | 2017-11-06 |
| JP5913367B2 (ja) | 2016-04-27 |
| US8709310B2 (en) | 2014-04-29 |
| ES2645769T3 (es) | 2017-12-07 |
| WO2012094381A2 (en) | 2012-07-12 |
| CA2823628A1 (en) | 2012-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201309346A (zh) | 噴霧乾燥萬古黴素 | |
| US20130172271A1 (en) | Pharmaceutical Spray Drying | |
| JP6038374B2 (ja) | 高純度ｐｔｈ含有凍結乾燥製剤およびその製造方法 | |
| BRPI0304821B1 (pt) | processo de preparação de uma suspensão estéril de partículas de corticosteróide para administração por inalação | |
| EP1574222B1 (en) | Sterilization process for steroids | |
| CN112423776B (zh) | 冻干方法和由该方法获得的替维瑞克-tfa冻干物 | |
| CN113425677B (zh) | 一种卡络磺钠水针注射液及其制备方法和应用 | |
| AU2014233800B2 (en) | Sterile S-adenosyl methionine with a high content of active isomer for injectable solutions, and procedure for obtaining it | |
| HK40067477A (en) | Methanesulfonic acid arbidol freeze-drying agent for aerosol inhalation | |
| CN118021738A (zh) | 药物组合物及其制备方法 | |
| ES2831019T3 (es) | Un procedimiento para el procesamiento de partículas de ingredientes farmacéuticos activos | |
| CN113940925A (zh) | 一种雾化吸入用甲磺酸阿比多尔冻干剂 | |
| HK1257291B (en) | Methods for inspecting a freeze-dried preparation containing a pth peptide and methods for producing a pharmaceutical product comprising the same | |
| HK1207825B (zh) | 高纯度含pth冷冻干燥制剂及其制造方法 | |
| HK1190304B (en) | Freeze-dried preparation containing high-purity pth and method for producing same |